NCT Number: NCT02904577
Prospective collection of data of possible prognostic relevance in patients with indolent non - follicular B-CELL Lymphomas.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Vienna Univ Med Int I, Vienna, Austria
The present study is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with non-follicular low grade B-cell lymphoma.
The study is aimed to verify whether a prognostic collection of data would allow the development of a more accurate prognostic assessment for non-follicular low grade B-cell lymphomas.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients registered in the study despite their planned treatment, watch and wait policy included. The "planned treatment" mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes.
Time frame: September 2024 (13 years)
Progression free survival (PFS) will be measured from the date of randomization to the date of documented first occurrence of disease progression or relapse or to the date of death from any cause. Patients who are lost to follow up will be censored at their last assessment date.
Time frame: September 2024 (13 years)
Progression free survival (PFS) will be measured from the date of randomization to the date of documented first occurrence of disease progression or relapse or to the date of death from any cause. Patients who are lost to follow up will be censored at their last assessment date.
Time frame: September 2024 (13 years)
Overall survival (OS) is defined as the time from the study entry until the date of death irrespective of cause. Patients who have not died at the time of end of the whole study , and patients who are lost to follow up , will be censored at the date of the last contact.
Time frame: September 2024 (13 years)
Event Free Survival (EFS) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression) or death from any cause.
Time frame: September 2017 (Six years)
Remission rate (RR) is defined as the number of complete and partial remission (CR and PR) after the completion of the first line of treatment.
Time frame: September 2016 (Five years)
Will be collected the risk factors potentially associated to the outcome of indolent non follicular lymphomas (clinical status, biochemistry, hemochrome, HCV, HBV and autoimmnity markers). Will be collected the risk factors potentially associated to the outcome of indolent non follicular lymphoma (clinical status, biochemistry, hemochrome, HCV, HBV and autoimmunity markers). Those risk factors will be utilized to obtain a prognostic model (prognostic index) from the Cox proportional hazard regression and, finally, a prognostic score grouping the prognostic index in at least three group of risk (low, intermediate, high risk).
Time frame: September 2024 (13 years)
In WW group the start of treatment will be treated as a time-varying covariate in Cox proportional hazard regression.
Time frame: September 2024 (13 years)
Remission rate (RR) is defined as the number of CR and PR after the second and subsequent lines of therapy, due to progression disease.
Fondazione Italiana Linfomi - ETS
Other
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03329950
Adenocarcinoma, Adnexal Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT06822829
Diffuse Large B Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases
Reggio Emilia, Italy
View Trial Details